BOCA RATON, Fla., June 29 /PRNewswire/ -- Breckenridge announced that it has entered an agreement with Chemo/Liconsa (Madrid, Spain) to develop and manufacturer terbinafine, generic version of Lamisil(R) tablets. The market for Lamisil(R) exceeds $800 million. Breckenridge signed a Letter of Intent in February 2007 to secure the marketing in the US for the ANDA; which is filed and pending FDA approval. FDA recently acknowledged the transfer of the ANDA to Breckenridge, and final approval is expected soon.
Breckenridge has an aggressive Product Development program and looks forward to adding more products to its ANDA portfolio.
Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is widely accepted in over 100 accounts; including Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets 100 products, more than 150 sku's, in most dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations.
Chemo/Liconsa is a chemical-pharmaceutical company, dedicated to the development, manufacture and commercialization of Active Pharmaceutical Ingredients and Finished Dosage Forms for the pharmaceutical industry, with a focus on the generic industry; as well as the commercialization of pharmaceutical specialities in the gynecological area. Chemo relies on 10 industrial facilities in Europe, Asia and Latin-America.
Lamisil(R) is a registered trademark of Novartis
Breckenridge Pharmaceutical, Inc.
CONTACT: Larry Lapila, Vice President Business Development of BreckenridgePharmaceutical, +1-860-828-8140, fax, +1-860-828-8142, firstname.lastname@example.org;or Eduardo Cantero of Chemo Laboratorios (Liconsa, S.A.), +34-949-34-97-00,fax, +34-949-26-68-37, email@example.com